Fortress Biotech (FBIO) and its majority-owned subsidiary, Helocyte, announced that the first patient was dosed in a multicenter, placebo-controlled and randomized Phase 2 clinical trial to evaluate Triplex, a cytomegalovirus, CMV, vaccine, when administered to human leukocyte antigen, HLA, matched related stem cell donors to reduce CMV events in patients undergoing hematopoietic stem cell transplantation, HSCT.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBIO: